SL Science Holding Limited
SLBTHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, SL Science Holding Limited focuses on Biotechnology services and products. SL Science Holding Limited manufactures cosmetic skin care and scalp care products. The $1.61B market capitalization puts SLBT squarely in small-cap range for its industry. The company's products include SL bio's milk-derived exosome essence, SL bio's tangerine-derived extract, and the MilkExo concentrate series.
Market Cap
$1.61B
Beta
—
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-0.01
EPS (Fwd)
—
ROE
—
ROA
—
Cash
$3.4M
Total Debt
$305,669
Free CF
—
52W Change
-69.5%
Annual Financials
Cash vs Debt
Where SLBT stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, SLBT finished 52.85% below its 150-day moving average ($7.02) and 58.10% below its 200-day moving average ($7.90). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SLBT overbought or oversold?
At the September 3, 2026 close, SLBT's RSI(14) was 74.6, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
SL Science Holding Limited holds $3.4M in cash against $306K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Revenue has been uneven over recent years, ranging from $879K to $2.2M.
With cash comfortably exceeding debt, SLBT has financial flexibility that may help navigate uncertain periods. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for SL Science Holding Limited and its sector.